Ibrutinib, as only one agent, is helpful in dealing with CLL, diverse subtypes of lymphoma and other B-cell malignancies Except unacceptable toxicity or disease development is noticed. On account of Persistent exposure of ibrutinib during therapy, lymphoma cells could achieve compensatory survival pathways, genetic mutations or clonal collection resulting in https://annei207xcf0.blogvivi.com/profile